Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.
first published: Nov 20, 2012 12:20 pm
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
